Susquehanna International Group, LLP Immutep LTD Call Options Transaction History

Susquehanna International Group, LLP

12 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$1.77 - $2.64 $16,815 - $25,080	-9,500 Reduced 7.61%	115,400 $255,000
Q2 2024 Aug 15, 2024	BUY	$1.87 - $3.23 $233,563 - $403,427	124,900 New	124,900 $251,000
Q4 2023 Feb 14, 2024	BUY	$1.76 - $2.49 $136,048 - $192,477	77,300 Added 235.67%	110,100 $264,000
Q3 2023 Nov 14, 2023	SELL	$1.75 - $2.37 $120,225 - $162,819	-68,700 Reduced 67.68%	32,800 $62,000
Q2 2023 Aug 11, 2023	BUY	$1.54 - $2.62 $140,140 - $238,420	91,000 Added 866.67%	101,500 $214,000
Q1 2023 May 16, 2023	SELL	$1.63 - $2.06 $54,931 - $69,422	-33,700 Reduced 76.24%	10,500 $17,000
Q4 2022 Feb 14, 2023	BUY	$1.6 - $2.53 $45,920 - $72,611	28,700 Added 185.16%	44,200 $77,000
Q3 2022 Nov 14, 2022	SELL	$1.56 - $2.29 $27,456 - $40,304	-17,600 Reduced 53.17%	15,500 $24,000
Q2 2022 Aug 15, 2022	SELL	$1.96 - $3.09 $29,792 - $46,968	-15,200 Reduced 31.47%	33,100 $67,000
Q1 2022 May 16, 2022	SELL	$2.3 - $3.61 $40,940 - $64,258	-17,800 Reduced 26.93%	48,300 $132,000
Q4 2021 Feb 14, 2022	SELL	$3.09 - $4.81 $166,242 - $258,777	-53,800 Reduced 44.87%	66,100 $217,000
Q3 2021 Nov 15, 2021	BUY	$3.17 - $4.39 $380,083 - $526,361	119,900 New	119,900 $464,000

1.86M

264K

90.5K

Ticker IMMP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 86,624,000
Market Cap $170M
Description
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.